

Preserving thrombosis and life years in polycythemia vera: start by reading the biology of the disease

Tiziano Barbui,¹ Arianna Ghirardi,¹ Annalisa Condorelli² and Marta Sobas³

¹FROM Research Foundation, ASST Papa Giovanni XXIII, Bergamo, Italy; ²Hematology Division, ASST Papa Giovanni XXIII, Bergamo, Italy and ³Department of Hematology, Faculty of Medicine, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Toruń, 85-168 Bydgoszcz, Poland

Correspondence: T. Barbui
tbarbui@fondazionefrom.it

Received: October 10, 2025.

Accepted: January 27, 2026.

Early view: February 5, 2026.

<https://doi.org/10.3324/haematol.2025.300028>

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license



Abstract

The Swedish nationwide study by Leontyeva *et al.*, published in *Haematologica* in September 2025, revealed that patients with myeloproliferative neoplasms (MPN) continue to lose life years compared with the general population, with polycythemia vera (PV) showing a 1.8-year loss in restricted mean survival at 15 years. Despite being classified as “low risk,” these younger patients lose more life years than age-matched peers. They face decades of exposure to clonal proliferation, inflammation, and thromboinflammation, which contribute to vascular injury, myelofibrosis, and secondary cancers. Evidence suggests that early, biology-guided therapy may modify this trajectory. Interferon (particularly ropeginterferon alfa-2b) and ruxolitinib reduce *JAK2*^{V617F} allele burden, systemic inflammation (as reflected by the neutrophil-to-lymphocyte ratio [NLR]), and thrombosis rates, demonstrating long-term disease-modifying potential. The challenge lies in identifying which younger patients should receive cytoreductive therapy, as these treatments, while effective, may be poorly tolerated or burdensome over decades. Biological markers such as persistent leukocytosis, elevated NLR, rising *JAK2*^{V617F} variant allele frequency, or high phlebotomy burden can guide treatment decisions more precisely than age alone. Tailoring therapy in younger PV patients according to disease biology and individual tolerance may prevent irreversible complications, improve quality of life, and ultimately reduce the number of life years lost.

Introduction

The recent Swedish study by Leontyeva *et al.*¹ draws attention to an important and still unresolved issue concerning patients with myeloproliferative neoplasms (MPN). Using a nationwide cohort and advanced statistical methods, the authors demonstrated that young patients with MPN have a shorter life expectancy than the general population. For polycythemia vera (PV) patients in particular, the loss in restricted mean survival time over 15 years is about 1.8 years, while across all MPN it reaches approximately 4.3 years. The study also provides sex-specific survival curves, showing that men and women have different background life expectancies and, in some cases, different excess mortality rates. As a result, the absolute years of life lost can differ by sex even when hazard ratios are similar. These findings shift the focus from short-term hematologic targets to what truly matters to patients: preserving life years. Interestingly, Leontyeva *et al.* pointed out that women and men do not lose the same number of years at a given age due to dif-

ferences in background life expectancy; the same hazard ratio can represent a greater number of years at risk for women.¹ In PV, sex differences in outcomes vary by series, but younger women may experience more venous events at unusual sites (e.g., splanchnic or cerebral), for which aspirin alone is inadequate. In this context, inherited and environmental contributors to thrombosis and, in young women, the added risks posed by hormonal contraceptives and pregnancy should also be considered. Therefore, it is reasonable to keep biological thresholds identical for both sexes and to provide sex-specific counselling regarding pregnancy planning, iron deficiency resulting from phlebotomy, and proactive management of venous risk.

This study prompted us to reflect not only on the loss of life years among patients under 60 years of age but also on the biological and clinical factors that may shorten survival in this population. Younger patients with PV warrant special attention because, although often labeled as “low risk” by European LeukemiaNet (ELN) criteria, they lose more years of life than age-matched peers and it remains

uncertain whether they require distinct thrombotic risk stratification. The paradox lies in the fact that, while free of prior thrombosis and under 40–60 years of age, these patients face prolonged exposure to clonal proliferation, inflammation, and thromboinflammatory injury, processes that promote vascular damage, myelofibrosis, and secondary cancers.^{2–4} Since younger individuals have naturally longer life expectancy, even modest excess mortality translates into significant numbers of years of life lost.

Current risk stratification, therefore, underestimates the true biological hazard in these patients. A purely age-based definition of “low risk” may delay disease-modifying therapy in those who, based on their biological profile, would benefit most. A proactive management approach for selected younger patients is thus biologically and clinically justified, and may be crucial for preserving long-term survival and quality of life.

In this Perspective Article, we aim to explore how best to reduce excess mortality in young patients with PV and to define the most meaningful therapeutic endpoints for this population, considering not only short-term toxicity but also the potential long-term consequences of treatment. To achieve this, we integrate and interpret recent epidemiologic and biological evidence, with the goal of stimulating a broader discussion on how to minimize years of life lost in PV. Our intention is to connect population-level observations, such as those emerging from the Swedish nationwide study, with mechanistic insights and evolving therapeutic data, ultimately proposing a forward-looking framework to guide clinical decision-making and inform the design of future trials in younger patients with PV.

Why young patients with polycythemia vera require a different perspective

Regardless of age, thrombosis remains a defining feature of PV. Real-world data show that even very young patients (≤ 25 years) have a substantial thrombotic burden: 21.5% present with prior thrombosis at diagnosis and 16.3% experience recurrence during follow-up.⁵ The pattern, however, differs from older patients; young individuals show a higher proportion of venous events, including splanchnic and other unusual sites, whereas arterial events are less common due to the absence of traditional cardiovascular risk factors. The mechanisms underlying venous thrombosis remain unclear but may involve chronic inflammation, as young PV patients also display elevated inflammatory cytokines compared with the general population. These inflammatory pathways contribute not only to thrombosis but also to symptom burden: fatigue, microvascular disturbances, and impaired quality of life may be particularly impactful in this age group, interrupting and compromising

education, career development, family planning, and social participation.⁶

Moreover, as pointed out by Leontyeva *et al.*,¹ when compared with age-matched controls in the general population, younger individuals with PV experience a disproportionately greater excess mortality and lose more years of life. This long-term attrition reflects the cumulative incidence of complications, including recurrent thrombosis, progression to myelofibrosis or acute leukemia, and second malignancies occurring over decades of disease. Together, these patients have unique vulnerabilities and require therapeutic strategies that look beyond short-term hematocrit control and that aim, instead, to modify the long-term natural history of the disease.

Evidence that early intervention may safeguard against complications and preserve life years

A key question is whether there is evidence to support early pharmacological intervention in order to reduce the number of years of life lost and prevent major complications such as thrombosis and the evolution of the disease into myelofibrosis (MF), as well as the development of solid tumors in younger patients with MPN, particularly PV. Recent observational studies have addressed this issue. Abu-Zeinah *et al.*² demonstrated that patients diagnosed at a younger age experience higher excess mortality than older patients compared to their age-matched peers. In line with the findings of Leontyeva *et al.*,¹ these younger patients experience a greater loss of relative survival time, although younger individuals with PV, essential thrombocythemia (ET) or primary myelofibrosis (PMF) who are under 60 years of age will still live longer in absolute terms. This pattern was observed across all MPN subtypes, but was most pronounced in PV and PMF, where there is excess cardiovascular and cancer-related mortality. Their findings show that younger patients are vulnerable to the cumulative consequences of decades of chronic inflammation if they do not receive adequate treatment.

Drawing on their prior work, these authors showed that interferon- α emerges as the only therapy consistently associated with reduced MF progression, cancer-related mortality, and potential restoration of near-normal life expectancy in PV.⁷ They argued that age alone should not delay the implementation of disease-modifying strategies or prevent younger patients from accessing timely therapy or participating in clinical trials.

Reports in adolescents and young adults (AYA) showed that thrombosis can develop at an early stage and that progression to MF or acute leukemia is not uncommon.⁵ In these younger individuals, the biology of the disease also differs; in ET, triple-negative cases are more prevalent, inflamma-

tory cytokine levels are higher, and the mutational load is smaller than in older adults. These findings suggest that young patients should not simply be reassured because they are “low risk” according to adult criteria. Treatment should be tailored to the individual and interferon should be considered at an earlier stage if biological risk is evident. Hydroxyurea (HU) remains an option when interferon is not tolerated or contraindicated. Current data suggest that, for long-term goals, interferon-based drugs are the preferred first-line option, in line with ELN guidelines.

In the largest series of AYA with ET or PV (aged <25 years; N=348), the thrombotic rate was approximately 1.9 per 100 patient-years, which is similar to that observed in older cohorts.⁶ Standard adult risk scores did not predict thrombosis; instead, leukocytosis ($>11 \times 10^9/L$) was the main predictor. Progression to myelofibrosis in ET occurred at a rate of approximately 0.7 per 100 patient-years, and was associated with *CALR* mutations and prior thrombosis.⁵ Importantly, first-line interferon therapy was associated with improved MF-free survival and no progression was observed in patients who started treatment with interferon.⁶ The above-mentioned studies were observational in nature but consistently support the use of interferon as first-line choice in young people with PV; its favorable efficacy has been demonstrated in randomized clinical trials. In the PROUD/CONTINUATION-PV trial,⁸ pegylated interferon alfa-2b was compared with hydroxyurea and showed higher complete hematologic response rates, a greater reduction in *JAK2*^{V617F} variant allele frequency, and significant improvement in event-free survival (EFS). A smaller phase III trial similarly demonstrated that pegylated IFN- α 2a was superior to HU in reducing the *JAK2*^{V617F} allele burden but was equally efficacious to HU in terms of hematologic response.⁹

In addition, evidence supporting early use of interferon in younger, low-risk patients derives from the Low-PV phase II randomized trial.¹⁰⁻¹² In this study, younger PV patients classified as low risk for thrombosis according to ELN criteria were randomly assigned to low-dose ropeginterferon alfa-2b (100 μ g every 2 weeks) versus phlebotomy. At 12–24 months, ropeginterferon provided superior disease control, maintaining hematocrit $\leq 45\%$ without disease progression more effectively than phlebotomy, reducing the need for additional phlebotomies, improving symptoms, and achieving partial molecular responses (defined as $>50\%$ reduction in *JAK2*^{V617F} VAF) in approximately 55% of patients. Among those who remained on treatment, the primary endpoint was sustained in 97%, 94%, and 94% at years 3, 4, and 5, respectively, with 60% of patients remaining phlebotomy-free. Notably, an early high phlebotomy requirement (>3 in 6 months) predicted failure of phlebotomy-only management, suggesting the need for a transition to IFN. Thus, in young, low-risk PV patients, low-dose peg-IFN alfa 2b offers clear advantages over phlebotomy-based approaches, delivering superior hematologic control, fewer

phlebotomies, meaningful molecular responses, and durable long-term efficacy with an acceptable safety profile. It is noteworthy that a favorable response to interferon has been found to depend on clonal tumor burden and the benefit appears greater when treatment is started early, before the mutant clone has had time to expand, as is typically seen in low-risk PV cases.⁸ In patients with PV who did not receive IFN in the early phase of the disease, *JAK2*^{V617F} VAF approximately doubles every 1.4 years. Conversely, most responders to IFN showed a steady reduction in clone size; some experienced a gradual decline (half-life approx. 1.6 years), whereas many exhibited a two-phase decline with a faster long-term reduction indicating later but more sustained responses.

A low starting dose with gradual titration to achieve complete hematologic response is advised. Once a stable response is achieved, dose reduction may be appropriate, and treatment discontinuation can be considered in patients who maintain a deep molecular response (*JAK2*^{V617F} VAF $<10\%$) for at least two years.¹³

Although profound, durable reductions in *JAK2*^{V617F} allele burden appear clinically meaningful, and the neutrophil-to-lymphocyte ratio (NLR) may serve as a practical surrogate of *JAK2* suppression,^{14,15} there are still no standardized recommendations on monitoring VAF or determining when IFN therapy can be safely discontinued.¹³ While peg-interferon alfa-2a and alfa-2b have a well-established safety profile in the short- and medium-term, patients (especially younger individuals) should be informed that long-term safety data are still being collected. This uncertainty should be incorporated into shared decision-making. A thorough baseline eligibility assessment is recommended to ensure safe use. Typically, this includes evaluation of mental health history, screening for autoimmune disorders, thyroid function testing, and routine liver and kidney function tests to identify patients who may require closer monitoring.

Unfortunately, some patients do not respond to or are intolerant of the drug, and therefore require an individualized approach. Options include dose adjustment or switching to alternative agents such as HU or ruxolitinib, particularly if a thrombotic event occurs during interferon therapy. Evidence from the RESPONSE trials¹⁶ and real-world cohorts, including patients previously exposed to interferon, shows that ruxolitinib provides durable hematocrit and symptom control with predictable tolerability. Short-term toxicity mainly involves manageable cytopenias and mild infections, while long-term safety remains stable, with no excess leukemic progression but a recognized need for dermatologic and herpes-zoster surveillance.

Unlike HU and other cytoreductive therapies that have historically raised concerns about leukemogenic potential, long-term follow-up of patients treated with interferon has not demonstrated an increased risk of leukemic transformation. Recent reviews emphasize that interferon maintains a favorable long-term safety profile, with no

evidence to support either a leukemogenic effect or an excess of secondary cancers; together, these data reinforce the view that interferon may represent a safer long-term therapeutic option with respect to both leukemogenesis risks.¹³ Additionally, emerging data suggest that intermittent or de-escalated interferon dosing strategies may be feasible, potentially improving tolerability and cost-efficiency without compromising disease control.

With regard to cost, two studies have specifically addressed this issue and calculated that interferon, particularly ropeginterferon alfa-2b, is a cost-effective treatment option for patients with PV when assessed over extended time periods.^{17,18} Both US and European analyses conclude that, despite higher upfront drug costs, the long-term clinical benefits (reduced need for phlebotomy, improved hematologic control, and potential disease-modifying effects) justify the overall economic cost.

Two biologically promising agents are under evaluation: Bomedemstat, an LSD1 inhibitor,¹⁹ and Givinostat, an HDAC inhibitor, fast-tracked by the US Food and Drug Administration in May 2025.²⁰ However, concerns about toxicity remain central to defining their role in younger patients.

Does preventing vascular complications attenuate polycythemia vera disease evolution and help reduce the number of life years lost?

Thrombosis is a leading cause of death in PV, accounting for roughly one-third of all fatalities.²¹ Preventing vascular complications may not only avert catastrophic organ damage but also attenuate disease evolution that manifests decades after diagnosis. Thrombosis, inflammation, and PV progression are increasingly understood to be components of a self-reinforcing biological circuit.

Vascular events are not isolated clinical accidents, but rather manifestations of a chronic inflammatory environment driven by *JAK2*^{V617F}.^{22,23} Each thrombotic or atherosclerotic episode amplifies IL-1 β , TNF and NF- κ B signaling, thereby reinforcing neutrophil activation, neutrophil extracellular trap (NET) formation, and platelet-leukocyte interaction.²⁴⁻²⁸ This inflammatory amplification increases the likelihood of recurrent thrombosis and fosters a bone marrow environment conducive to fibrosis and clonal expansion. Therefore, interrupting this cycle by preventing vascular events may represent a genuine disease-modifying intervention.^{23,29,30} Several clinical and biological observations support this view. Elevated leukocyte counts, a high NLR, and increased C-reactive protein, markers of systemic inflammation, are strongly associated with both thrombosis and progression to MF or leukemia.^{31,32} Therapies that normalize these parameters, are associated with improved EFS. The early use of interferon not only prevents vascular complications but

may also reduce the *JAK2*^{V617F} allele burden. It is hypothesized that it limits the emergence of additional clones that drive disease evolution; however, definitive proof of this effect is not yet available and current evidence is largely observational.

Preventing thrombotic events also preserves organ integrity. Arterial and venous thromboses often lead to irreversible damage to the heart, brain, liver, or other organs, each of which contributes to premature death, regardless of hematologic control.^{33,34} Therefore, avoiding these complications extends survival by reducing immediate mortality and preventing long-term organ failure and disability. Furthermore, minimizing phlebotomy reduces iron deficiency and secondary thrombocytosis, which can exacerbate microvascular ischemia and fatigue, and predispose to major thrombosis. In a multistate analysis of 1,545 PV patients, incident thrombosis, mainly arterial, was associated with earlier progression to post-PV MF and increased mortality.³⁵ In the REVEAL study, a history of thrombosis predicted subsequent MF progression and death, alongside longer disease duration and leukocytosis.³⁴

In addition, there is growing evidence that thrombosis can also be associated with a higher risk of solid tumors in the general population.³⁶ A multicenter nested case-control study of MPN showed that post-diagnosis thrombosis may predict the development of solid tumors later in life.^{37,38} Among the source cohort, 647 patients who developed a second solid cancer (cases) were each matched with two MPN controls without cancer (N=1,234). The primary exposure was incident thrombosis after MPN diagnosis, analyzed separately as arterial or venous/splanchnic. Overall outcomes were carcinoma.

A parallel analysis showed that frequency of non-melanoma skin cancer was significantly and independently higher after HU or ruxolitinib. HU use was associated with a higher risk of non-melanoma skin cancer (OR 2.08; 95%CI: 1.09-3.98).³⁸ Interestingly, aspirin use was associated with a lower risk of carcinoma (OR 0.64; 95%CI: 0.47-0.87). Incident arterial thrombosis was independently associated with subsequent carcinoma using multivariable conditional logistic regression (OR 1.97; 95%CI: 1.14-3.41; *P*=0.015), whereas venous thrombosis was not (OR 1.03; 95%CI: 0.58-1.82). The median timing of arterial events was approximately four years before cancer occurrence. An age-stratified analysis revealed that the arterial-then-cancer sequence was an independent predictor, particularly in patients under 60 years of age.⁴ The study has limitations, including its retrospective design and potential confounding by indication. However, the results support a mechanistic link between arterial immunothrombosis, chronic inflammation and oncogenesis, suggesting the need for earlier anti-inflammatory and cytoreductive strategies.

Similar patterns were observed outside MPN, where myocardial infarction, stroke, and limb ischemia often precede solid tumors, suggest shared biological pathways, including

chronic inflammation, oxidative stress, metabolic dysfunction, microbial dysbiosis, clonal hematopoiesis of indeterminate potential (CHIP), hormonal factors, and cellular senescence, with inflammation playing a central role.³⁹⁻⁴¹ Supporting this link, the CANTOS trial, the largest study of cytokine inhibition, demonstrated that IL-1 β blockade not only reduced cardiovascular events but also decreased lung cancer incidence and cancer-related mortality.⁴² These findings highlight the convergence of IL-1 β biology in thrombosis and cancer, and the potential of IL-1 β -targeted therapy to address both.⁴³

Taken together, the current evidence suggests that preventing vascular complications could affect the long-term course of PV by stopping the *JAK2*-driven clonal disease and the cycle of inflammation and thrombosis. The associations between thrombosis, MF progression, and cancer risk are biologically plausible and consistent with the central role of chronic inflammation, as previously mentioned. However, these observations are largely derived from retrospective analyses and observational cohorts, and require confirmation in prospective studies specifically designed to evaluate disease evolution and long-term outcomes. They should, therefore, be considered provisional until validated by additional clinical evidence.

How to recognize the aggressive biology of polycythemia vera

Recognizing and monitoring the biological activity of PV is key to identifying patients at risk of progression and determining when to initiate disease-modifying therapy.^{44,45} Biological activity reflects the combined effects of clonal proliferation, inflammatory activation, and immune dysregulation, which together drive vascular injury, fibrosis, and reduced survival.⁴⁶ *JAK2*^{V617F} remains the defining molecular hallmark of PV and best surrogate for disease burden, as demonstrated in both randomized clinical trials and observational studies. Rising *JAK2*^{V617F} VAF is linked to thrombosis, clonal expansion, and myelofibrosis, while its reduction with interferon, ruxolitinib, or transplantation correlates with improved EFS and fewer vascular events. Non-driver mutations (*TET2*, *DNMT3A*, *ASXL1*) refine prognosis⁴⁷ and modulate therapy response but do not replace *JAK2*^{V617F} as the principal biological marker.⁴⁸

Inflammation lies at the heart of MPN biology, and the NLR provides a simple and consistent insight into this. The *JAK2*^{V617F} mutation increases the number of myeloid cells while reducing the number of lymphoid cells, naturally driving the NLR up; so a high NLR often signals both systemic inflammation and a more aggressive clone.⁴⁹ In PV, patients with a baseline NLR of at least 3.5 have a longer disease duration, greater splenomegaly, a higher *JAK2*^{V617F} allele burden and more classic hyperproliferative features than those with an NLR below 3.5.¹⁴ Treatment matters:

ropeginterferon substantially lowers the NLR, particularly in patients with a high baseline NLR, and its decline closely tracks reductions in *JAK2*^{V617F}, linking inflammatory control to clonal suppression.¹⁴ Across the PROUD/CONTINUATION-PV trials, ropeginterferon produced deeper reductions in NLR over 60 months than HU, the effect of which waned, and which does not meaningfully lower *JAK2* burden.^{15,50} In the ECLAP study, propensity-matched HU *versus* phlebotomy showed no meaningful fall in NLR at 12 months, highlighting the limited anti-inflammatory impact of HU.¹⁵

From a clinical perspective, NLR carries significant prognostic value: time-dependent analyses demonstrate that an NLR of ≥ 3.3 is associated with an increased risk of total thrombosis, whereas leukocytosis loses significance.¹⁵ Furthermore, sustained reductions in NLR are associated with improved EFS. Joint models confirm that a one-unit increase in NLR is associated with an approximately 10% higher risk of thrombosis and death, independently of age, HU use, or cardiovascular factors.¹⁵ Recognizing heightened biological activity, through rising VAF, persistent leukocytosis, or elevated NLR, should prompt early intervention. By controlling this biological sequence early, especially in younger patients, vascular injury may be prevented, and disease evolution delayed or avoided, promoting longer survival.⁷

Of note, in line with what has been seen with Roppeginterferon alfa 2b, PV patients resistant/intolerant to HU with high NLR had elevated white blood cell counts, increased neutrophils, reduced lymphocytes, and significantly higher *JAK2*^{V617F} VAF. Importantly, under ruxolitinib treatment, only the high-NLR group showed a marked and sustained reduction in NLR, primarily driven by a selective decrease in neutrophils.⁵¹ This was paralleled by a significant decline in *JAK2*^{V617F} VAF. Similar results were reported in the MAJIC study,⁵² indicating that ruxolitinib response is linked to prolonged EFS, and progression-free and overall survival in HU-resistant PV patients. However, in this latter trial, NLR was not examined in relationship with the suppression of *JAK2* or EFS.

Overall, NLR emerged as a simple yet powerful biomarker, reflecting both clonal and inflammatory dynamics, especially in patients starting therapy with higher NLR values. The potential utility of NLR also emerged from data indicating a large cardiovascular prevention in the general population. IL-1 β blockade with canakinumab, a monoclonal antibody targeting IL-1 β , is one of the interventions capable of lowering NLR by reducing neutrophil levels while sparing lymphocytes.⁴³ Since IL-1 β signaling plays a central role in *JAK2*-driven hematopoiesis and inflammation, anti-IL-1 β monoclonal antibodies could be considered as a rational adjunct to cytoreductive drugs. Such combination therapies could provide a targeted approach to modulate the inflammatory axis without compromising lymphocyte-mediated immune surveillance, an important finding, particularly for younger patients.

Conclusion and future perspective

Although younger patients with PV live longer in absolute terms than older patients, they still lose measurable years of life compared with their peers. This reflects the biology of a proliferative and inflammatory disease rather than aging itself. Stable disease may warrant observation, but once biological activity emerges, early cytoreductive therapy should be considered. Meaningful progress in reducing life years lost will depend on moving beyond traditional, age-based risk models toward biology-driven, and potentially sex-informed, treatment strategies. Future prospective trials should test whether early, biology-guided interventions can prevent vascular injury, delay progression, and improve survival.

Ultimately, reducing the years of life lost in PV will require translating disease biology into everyday clinical practice. The focus must shift from conventional hematologic control to strategies that truly extend life expectancy by preventing vascular injury and delaying disease progression while posing no major safety risks.

Disclosures

TB reports a research grant from GSK and AOP, and Advisory Board for AOP; MS reports honoraria from Novartis, Celgene, AOP Orphan and AbbVie; AG and AC have no conflicts of interest to disclose.

Contributions

TB, AG, AC and MS contributed to the conceptualization of this Perspective Article and to the literature review; TB wrote the original draft that was approved by all authors.

Funding

This work is part of the RICO project (Ricerca Istituzionale Collaborativa-Ospedale Papa Giovanni XXIII di Bergamo) supported by “Bottega del Riuso di Mano in Mano” (Caritas Parrocchiale di Clusone), Italy.

Data-sharing statement

Aggregated data available by request to the Corresponding Author. Patient-level data will not be shared due to privacy concerns.

References

- Leontyeva Y, Landtblom AR, Hultcrantz M, et al. Loss of life expectancy in patients with myeloproliferative neoplasms in Sweden. *Haematologica*. 2026;111(3):990-996.
- Abu-Zeinah K, Saadeh K, Silver RT, Scandura JM, Abu-Zeinah G. Excess mortality in younger patients with myeloproliferative neoplasms. *Leuk Lymphoma*. 2023;64(3):725-729.
- Hansen IO, Sørensen AL, Hasselbalch HC. Second malignancies in hydroxyurea and interferon-treated Philadelphia-negative myeloproliferative neoplasms. *Eur J Haematol*. 2017;98(1):75-84.
- Ghirardi A, Carobbio A, Guglielmelli P, et al. Age-stratified analysis reveals arterial thrombosis as a predictor for gender-related second cancers in myeloproliferative neoplasms: a case-control study. *Blood Cancer J*. 2024;14(1):68.
- Sobas M, Kiladjian J-J, Beauverd Y, et al. Real-world study of children and young adults with myeloproliferative neoplasms: identifying risks and unmet needs. *Blood Adv*. 2022;6(17):5171-5183.
- Beauverd Y, Ianotto J-C, Thaw KH, et al. Impact of treatment for adolescent and young adults with essential thrombocythemia and polycythemia vera. *Leukemia*. 2025;39(5):1135-1145.
- Abu-Zeinah G, Krichevsky S, Cruz T, et al. Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. *Leukemia*. 2021;35(9):2592-2601.
- Kiladjian J-J, Klade C, Georgiev P, et al. Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b. *Leukemia*. 2022;36(5):1408-1411.
- Mascarenhas J, Kosiorek HE, Prchal JT, et al. A randomized phase 3 trial of interferon- α vs hydroxyurea in polycythemia vera and essential thrombocythemia. *Blood*. 2022;139(19):2931-2941.
- Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon alfa-2b versus phlebotomy in low-risk patients with polycythaemia vera (Low-PV study): a multicentre, randomised phase 2 trial. *Lancet Haematol*. 2021;8(3):e175-e184.
- Barbui T, Vannucchi AM, De Stefano V, et al. Ropeginterferon versus standard therapy for low-risk patients with polycythemia vera. *NEJM Evid*. 2023;2(6):EVIDoA2200335.
- Barbui T, Carobbio A, De Stefano V, et al. Ropeginterferon phase 2 randomized study in low-risk polycythemia vera: 5-year drug survival and efficacy outcomes. *Ann Hematol*. 2024;103(2):437-442.
- Kiladjian J-J. Pegylated interferon: the who, why, and how. *Hematology Am Soc Hematol Educ Program*. 2024;2024(1):535-540.
- Barbui T, Carobbio A, Guglielmelli P, et al. Neutrophil/lymphocyte ratio identifies low-risk polycythaemia vera patients for early ropeginterferon alfa-2b therapy. *Br J Haematol*. 2024;205(6):2287-2294.
- Barbui T, Ghirardi A, Empson V, et al. Neutrophil-to-lymphocyte ratio as surrogate for JAK2V617F suppression and event-free survival in polycythemia vera. *Blood Cancer J*. 2025;15(1):132.
- Passamonti F, Griesshammer M, Palandri F, et al. Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study. *Lancet Oncol*. 2017;18(1):88-99.
- Gerds AT, Castro C, Snopek F, et al. Cost-effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera. *J Comp Eff Res*. 2023;12(9):e230066.
- Walter E, Torelli F, Barbui T. Cost-utility analysis of ropeginterferon alfa-2b to manage low-risk patients with polycythemia vera as compared to phlebotomy only in the Austrian healthcare system. *Ann Hematol*. 2025;104(1):219-229.
- Krecak I, Lucijanac M, Verstovsek S. Advances in risk stratification and treatment of polycythemia vera and essential thrombocythemia. *Curr Hematol Malig Rep*. 2022;17(5):155-169.
- Chifotides HT, Bose P, Verstovsek S. Givinostat: an emerging treatment for polycythemia vera. *Expert Opin Investig Drugs*. 2020;29(6):525-536.
- Gerds AT, Mesa RA, Burke JM, et al. Association between elevated white blood cell counts and thrombotic events in

- polycythemia vera: analysis from REVEAL. *Blood*. 2024;143(16):1646-1655.
22. Hermouet S, Hasselbalch HC. Interleukin-1 β , JAK2V617F mutation and inflammation in MPNs. *Blood Adv*. 2024;8(16):4344-4347.
 23. Hasselbalch HC. Perspectives on chronic inflammation in essential thrombocythemia, polycythemia vera, and myelofibrosis: is chronic inflammation a trigger and driver of clonal evolution and development of accelerated atherosclerosis and second cancer? *Blood*. 2012;119(14):3219-3225.
 24. Shetty S, Subramanian M. Neutrophil extracellular traps (NETs) as drivers of atherosclerosis: pathogenic mechanisms and therapeutic opportunities. *Pharmacol Ther*. 2025;274:108917.
 25. Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. *Sci Transl Med*. 2018;10(436):eaan8292.
 26. Brinkmann V, Reichard U, Goosmann C, et al. Neutrophil extracellular traps kill bacteria. *Science*. 2004;303(5663):1532-1535.
 27. Kleppe M, Kwak M, Koppikar P, et al. JAK-STAT pathway activation in malignant and non-malignant cells contributes to MPN pathogenesis and therapeutic response. *Cancer Discov*. 2015;5(3):316-331.
 28. Rahman MF-U, Yang Y, Le BT, et al. Interleukin-1 contributes to clonal expansion and progression of bone marrow fibrosis in JAK2V617F-induced myeloproliferative neoplasm. *Nat Commun*. 2022;13(1):5347.
 29. Arranz L, Arriero MDM, Villatoro A. Interleukin-1 β as emerging therapeutic target in hematological malignancies and potentially in their complications. *Blood Rev*. 2017;31(5):306-317.
 30. Longhitano L, Li Volti G, Giallongo C, et al. The role of inflammation and inflammasome in myeloproliferative disease. *J Clin Med*. 2020;9(8):2334.
 31. Barbui T, Carobbio A, Finazzi G, et al. Inflammation and thrombosis in essential thrombocythemia and polycythemia vera: different role of C-reactive protein and pentraxin 3. *Haematologica*. 2011;96(2):315-318.
 32. Carobbio A, Vannucchi AM, De Stefano V, et al. Neutrophil-to-lymphocyte ratio is a novel predictor of venous thrombosis in polycythemia vera. *Blood Cancer J*. 2022;12(2):28.
 33. Barbui T, Ghirardi A, Carobbio A, et al. Thrombosis in myeloproliferative neoplasms: a viewpoint on its impact on myelofibrosis, mortality, and solid tumors. *Blood Cancer J*. 2024;14(1):188.
 34. Grunwald MR, Zwicker JI, Gerds AT, et al. A real-world evaluation of risk factors for disease progression in patients with polycythemia vera (PV) enrolled in REVEAL. *Blood*. 2023;142(Suppl 1):385.
 35. Barbui T, Carobbio A, Thiele J, et al. The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients. *Blood Cancer J*. 2023;13(1):187.
 36. Van Linthout S. Shared mechanisms in cancer and cardiovascular disease: S100A8/9 and the NLRP3 inflammasome: JACC: CardioOncology State-of-the-Art Review. *JACC CardioOncol*. 2025;7(5):501-513.
 37. Barbui T, Ghirardi A, Masciulli A, et al. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study. *Leukemia*. 2019;33(8):1996-2005.
 38. De Stefano V, Ghirardi A, Masciulli A, et al. Arterial thrombosis in Philadelphia-negative myeloproliferative neoplasms predicts second cancer: a case-control study. *Blood*. 2020;135(5):381-386.
 39. Rinde LB, Småbrekke B, Hald EM, et al. Myocardial infarction and future risk of cancer in the general population-the Tromsø Study. *Eur J Epidemiol*. 2017;32(3):193-201.
 40. Liu X, Adami H-O, Wåsterlid T, et al. Association of pre-diagnostic clonal hematopoiesis of indeterminate potential with prognosis among patients with cancer. *Am J Hematol*. 2025;100(11):1993-2003.
 41. Rioux B, Touma L, Nehme A, Gore G, Keezer MR, Gioia LC. Frequency and predictors of occult cancer in ischemic stroke: a systematic review and meta-analysis. *Int J Stroke*. 2021;16(1):12-19.
 42. Ridker PM, MacFadyen JG, Thuren T, et al. Effect of interleukin-1 β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-blind, placebo-controlled trial. *Lancet*. 2017;390(10105):1833-1842.
 43. Adamstein NH, MacFadyen JG, Rose LM, et al. The neutrophil-lymphocyte ratio and incident atherosclerotic events: analyses from five contemporary randomized trials. *Eur Heart J*. 2021;42(9):896-903.
 44. Chee A, Mead AJ. Molecular profiling in MPN: who should have it and why? *Hematology Am Soc Hematol Educ Program*. 2024;2024(1):524-534.
 45. Patel AA, Odenike O. Genomics of MPN progression. *Hematology Am Soc Hematol Educ Program*. 2020;2020(1):440-449.
 46. Barbui T, Gavazzi A, Sciatti E, et al. Clonal hematopoiesis in myeloproliferative neoplasms confers a predisposition to both thrombosis and cancer. *Curr Hematol Malig Rep*. 2023;18(4):105-112.
 47. Pasquer H, Daltro de Oliveira R, Vasseur L, et al. Distinct clinico-molecular arterial and venous thrombosis scores for myeloproliferative neoplasms risk stratification. *Leukemia*. 2024;38(2):326-339.
 48. Moliterno AR, Kaizer H, Reeves BN. JAK2 V617F allele burden in polycythemia vera: burden of proof. *Blood*. 2023;141(16):1934-1942.
 49. Choi DC, Messali N, Uda NR, et al. JAK2V617F impairs lymphoid differentiation in myeloproliferative neoplasms. *Leukemia*. 2024;38(11):2487-2491.
 50. Gisslinger H, Klade C, Georgiev P, et al. Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study. *Lancet Haematol*. 2020;7(3):e196-e208.
 51. Paoli C, Guglielmelli P, Borgi G, et al. Changes in neutrophil-to-lymphocyte ratio (NLR) in patients with polycythemia vera treated with ruxolitinib reflect changes of JAK2 variant allele frequency (VAF). *Blood*. 2025;146(Suppl 1):5527.
 52. Harrison CN, Nangalia J, Boucher R, et al. Ruxolitinib versus best available therapy for polycythemia vera intolerant or resistant to hydroxycarbamide in a randomized trial. *J Clin Oncol*. 2023;41(19):3534-3544.